[
  {
    "ts": null,
    "headline": "How FDA Approval of Subcutaneous KEYTRUDA QLEX at Merck (MRK) Has Changed Its Investment Story",
    "summary": "In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, allowing for one- to two-minute administration across 38 solid tumor indications in adults. This regulatory milestone positions Merck to potentially extend KEYTRUDA's patient reach and competitive standing ahead of future biosimilar entrants. We'll look at how the FDA approval of KEYTRUDA QLEX could influence Merck's portfolio diversification and oncology leadership...",
    "url": "https://finnhub.io/api/news?id=432f3679d2a6a50fd70976ceaaabec2dcb714c5472030ca91bd051fd5c3e7a4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758983669,
      "headline": "How FDA Approval of Subcutaneous KEYTRUDA QLEX at Merck (MRK) Has Changed Its Investment Story",
      "id": 136904088,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, allowing for one- to two-minute administration across 38 solid tumor indications in adults. This regulatory milestone positions Merck to potentially extend KEYTRUDA's patient reach and competitive standing ahead of future biosimilar entrants. We'll look at how the FDA approval of KEYTRUDA QLEX could influence Merck's portfolio diversification and oncology leadership...",
      "url": "https://finnhub.io/api/news?id=432f3679d2a6a50fd70976ceaaabec2dcb714c5472030ca91bd051fd5c3e7a4b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Strong R&D Pipeline Drives Growth Outlook",
    "summary": "Regeneron remains a 'Strong Buy' amid investor concerns and strong drug performances. Read here for more financial analysis of REGN stock.",
    "url": "https://finnhub.io/api/news?id=3d4ba0704f1a3d97b6cda52ebfecc661b38899c3e02c095bd67bce24888f884c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758963632,
      "headline": "Regeneron: Strong R&D Pipeline Drives Growth Outlook",
      "id": 136900904,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/904246150/image_904246150.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Regeneron remains a 'Strong Buy' amid investor concerns and strong drug performances. Read here for more financial analysis of REGN stock.",
      "url": "https://finnhub.io/api/news?id=3d4ba0704f1a3d97b6cda52ebfecc661b38899c3e02c095bd67bce24888f884c"
    }
  }
]